However, our data show that while the single blockade of IL6R or CXCR2 could be efficacious in CML, this might not be the case for AML, in which the concomitant inhibition of their signals is critical to target AML ckit+ cells. The gene discussed is CXCR2; the disease is acute myeloid leukemia.